WAHL BRYAN (General Counsel) sold 16.3% of their position (12.44K shares) of TARSUS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $850.4K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 3/19/2026ACC: 0001841401-26-000007
Officer· General Counsel
Since Jan 2021
-12.44K
Net shares
Net seller
$850.4K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
12.44K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−4.08K
Price / share
$69.42
Trade value
$283.51K
% of position
5.3%
3/17/2026
76.40K→72.31K
Common Stock
Direct
Shares
−4.13K
Price / share
$68.71
Trade value
$283.43K
% of position
5.7%
3/18/2026
72.31K→68.19K
Common Stock
Direct
Shares
−4.23K
Price / share
$67.00
Trade value
$283.48K
% of position
6.2%
3/19/2026
68.19K→63.96K
Total
Net shares
−12.44K
Net value
-$850.42K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/17/2026 | S · Sale | −4.08K | $69.42 | $283.51K | 5.3% | 76.40K | 72.31K |
| Common Stock Direct | 3/18/2026 | S · Sale | −4.13K | $68.71 | $283.43K | 5.7% | 72.31K | 68.19K |
| Common Stock Direct | 3/19/2026 | S · Sale | −4.23K | $67.00 | $283.48K | 6.2% | 68.19K | 63.96K |
| Total | −12.44K | -$850.42K | ||||||
Derivative Transactions0
No derivative transactions reported